Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Candesartan in Asymptomatic DCM Genetic Carriers
NCT05321875Phase 3Recruiting
- Start
- Jun 2022
- Primary completion
- Jun 2026
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of candesartan in dilated cardiomyopathy (DCM). Started Jun 2022; status: recruiting.
02
Drugs
candesartan
03
Conditions
dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on NCT05321875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05321875.